Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection

Introduction. - The aim of this study was to evaluate biochemical recurrence-free survival (RFS) and to identify useful predictors of such survival in localized prostate cancer patients (cNO) and pelvic lymph node metastasis (pN +) treated with radical prostatectomy and pelvic lymph node dissection. Patients and methods. - This multicenter and retrospective study, assessed overall survival (OS), cancer specific survival (CSS) and biochemical recurrence-free survival (RFS), between January 2005 until December 2010 with 5 years of distance. We evaluated factors predicting long-term RFS in node positive prostate cancer patients. Results. - Thus, 30 patients were included. Median follow-up was 89.9 +/- 27.4 months. After surgery, patients were treated with surveillance (n = 4, 13.5%), adjuvant hormone therapy (n = 22, 73%) or combination of radio and hormone therapy, (n = 4, 13.5%). During the follow-up, 50% of patients had biochemical recurrence, with a mean time period of 38 30 months. Five and 10-year RFS were 57% and 41% respectively. Extra lymph nodes extension (P = 0.00021) and pathological margin status (P = 0.0065) were independent predictors of 5-year RFS. Conclusion. - Biochemical RFS of patients treated with radical prostatectomy and subclinical lymph node metastatic disease is adequate and multifactorial. However, this study identifies pathological margin status and extra lymph node extension as independent factors of b RFS. (C) 2017 Elsevier Masson SAS. All rights reserved.